adenocarcinoma

Displaying 9 studies

  • Parameters Associated with Adenoma Detection Rate in Colonoscopy Scottsdale/Phoenix, AZ

    The purpose of this study is to determine baseline ophthalmologic parameters in a group of practicing endoscopists, to evaluate whether these parameters correlate with adenoma detection rates (ADR) and to construct a reproducible and widely applicable screening protocol that can be used to test the adequacy of visual parameters in practicing endoscopists.

  • Role of Eicosanoids in Intestinal Biology Scottsdale/Phoenix, AZ

    The purpose of this study is to see how the DNA methylation (a biochemical process involved in cell development) is activated during initial tumor growth and tumor progression. In order to look at this in patients with colorectal cancer or adenoma we must look at their tissue collected during surgery. Fresh tissue is required in order to study the primary cells in culture.

  • Comparison of the Functional Results After Rectal Cancer Surgery Between Conventional and Robotic-Assisted Laparoscopy. Jacksonville, FL; Rochester, MN

    The purpose of this study is to compare the robotic approach and conventional laparoscopic approach for rectal cancer surgery to evaluate functional results in terms of bowel, urinary and sexual function. 

  • TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery Scottsdale/Phoenix, AZ; Rochester, MN

    This phase I trial studies the side effects and best dose of trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) when given together with radiation therapy in treating patients with rectal cancer that has come back, spread to other places in the body, or cannot be removed by surgery. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving TAS-102 with radiation therapy may kill ...

  • A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer Rochester, MN; Scottsdale/Phoenix, AZ

    This is a Phase 2, open-label, 2-part, multicenter study in subjects with MSS relapsed/refractory colorectal cancer. The primary objective of Part 1 is to evaluate the safety and tolerability of escalating doses of eFT508 in combination with a fixed dose of avelumab to determine the maximum tolerated dose (MTD) of eFT508 and to select a recommended dose for Part 2. The primary objective of Part 2 is to evaluate antitumor activity of eFT508 at the recommended dose in combination with avelumab or eFT508 monotherapy. Parts 1 and 2 will also evaluate pharmacokinetics (PK) and pharmacodynamics.

  • A Study of Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma Scottsdale/Phoenix, AZ

    The purpose of this study is to evaluate the safety and clinical activity of the combination of durvalumab with CV301 in combination with maintenance chemotherapy for patients with metastatic colorectal or pancreatic cancer whose disease is stable on, or responding to 1st line therapy for metastatic disease.

  • A Study to Evaluate the Safety and Effectiveness of the Augmented Endoscopy System for Mucosal Lesion Detection During Colonoscopy for Colon Rectal Cancer. Scottsdale/Phoenix, AZ; Jacksonville, FL; La Crosse, WI; Eau Claire, WI

    The purpose of this study is to confirm the performance of the CB-17-08 software as a medical device (SaMD) to help endoscopist during the colonoscopy procedure to find potential mucosal lesions, including polyps, adenomas and carcinomas, without significant noise disturbing the endoscopist attention, nor negative interference with the lesions detection than with the standard endoscopy video alone. The study will evaluate whether high-definition white-light (HDWL) colonoscopy using CB-17-08 SaMD will have a lower miss rate of clinically significant polyps, as compared to standard HDWL colonoscopy alone (the current standard of care for colonoscopy).

  • A Study of SC-007 in Subjects With Advanced Cancer Rochester, MN

    This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC followed by Part A in participants with gastric cancer. Part B (dose expansion) will enroll participants into separate disease specific cohorts of CRC or gastric cancer.

  • A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer Scottsdale/Phoenix, AZ

    This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 weeks) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal or pancreatic adenocarcinoma.

.

Mayo Clinic Footer